User login
Key clinical point: High-dose eicosapentaenoic acid (EPA) monotherapy for 12 weeks showed superior efficacy, safety, and tolerability in patients with episodic migraine (EM), emphasizing its potential as a promising prophylactic option for managing EM.
Major finding: At 12 weeks, EPA vs placebo significantly improved monthly migraine frequency (P = .001), frequency of acute headache medication usage (P = .035), and headache severity (P = .030). No serious adverse events (AE) were reported, and no patients discontinued treatment due to intolerable AE.
Study details: This 12-week randomized, double-blind, placebo-controlled clinical trial included 70 patients with EM who were randomly assigned to receive high-dose EPA (1800 mg/day; n = 70) or placebo (n = 70).
Disclosures: This study was supported by grants from Kuang Tien General Hospital, the Ministry of Science and Technology, the National Science and Technology Council (NSTC) in Taiwan, and others. The authors declared no conflicts of interest.
Source: Wang H-F, Liu W-C, Zailani H, et al. A 12-week randomized, double-blind clinical trial of eicosapentaenoic acid intervention in episodic migraine. Brain Behav Immun. 2024;18:459-467 (Mar 16). doi: 10.1016/j.bbi.2024.03.019 Source
Key clinical point: High-dose eicosapentaenoic acid (EPA) monotherapy for 12 weeks showed superior efficacy, safety, and tolerability in patients with episodic migraine (EM), emphasizing its potential as a promising prophylactic option for managing EM.
Major finding: At 12 weeks, EPA vs placebo significantly improved monthly migraine frequency (P = .001), frequency of acute headache medication usage (P = .035), and headache severity (P = .030). No serious adverse events (AE) were reported, and no patients discontinued treatment due to intolerable AE.
Study details: This 12-week randomized, double-blind, placebo-controlled clinical trial included 70 patients with EM who were randomly assigned to receive high-dose EPA (1800 mg/day; n = 70) or placebo (n = 70).
Disclosures: This study was supported by grants from Kuang Tien General Hospital, the Ministry of Science and Technology, the National Science and Technology Council (NSTC) in Taiwan, and others. The authors declared no conflicts of interest.
Source: Wang H-F, Liu W-C, Zailani H, et al. A 12-week randomized, double-blind clinical trial of eicosapentaenoic acid intervention in episodic migraine. Brain Behav Immun. 2024;18:459-467 (Mar 16). doi: 10.1016/j.bbi.2024.03.019 Source
Key clinical point: High-dose eicosapentaenoic acid (EPA) monotherapy for 12 weeks showed superior efficacy, safety, and tolerability in patients with episodic migraine (EM), emphasizing its potential as a promising prophylactic option for managing EM.
Major finding: At 12 weeks, EPA vs placebo significantly improved monthly migraine frequency (P = .001), frequency of acute headache medication usage (P = .035), and headache severity (P = .030). No serious adverse events (AE) were reported, and no patients discontinued treatment due to intolerable AE.
Study details: This 12-week randomized, double-blind, placebo-controlled clinical trial included 70 patients with EM who were randomly assigned to receive high-dose EPA (1800 mg/day; n = 70) or placebo (n = 70).
Disclosures: This study was supported by grants from Kuang Tien General Hospital, the Ministry of Science and Technology, the National Science and Technology Council (NSTC) in Taiwan, and others. The authors declared no conflicts of interest.
Source: Wang H-F, Liu W-C, Zailani H, et al. A 12-week randomized, double-blind clinical trial of eicosapentaenoic acid intervention in episodic migraine. Brain Behav Immun. 2024;18:459-467 (Mar 16). doi: 10.1016/j.bbi.2024.03.019 Source